NEW YORK (GenomeWeb News) – The prenatal genetic testing company Cellscape said that Ted Snelgrove has become its new CEO, effective last week.
Snelgrove previously was VP of sales and marketing for Genomic Health, where he led the commercial development and launch of the Oncotype Dx test. He most recently was chief commercial officer for Crescendo Bioscience, and he has worked in business development, marketing, and product management at Amgen, ALZA, Immunex, and Eli Lilly.
ImmunID said this week that it has appointed Bernhard Sixt to be company president and CEO, and Nicolas Pasqual, the firm's co-founder and former CEO, to be its chief scientific officer.
Sixt co-founded Agendia and served as its CEO from 2003 to 2011, and he has over 25 years of experience in the development and commercialization of diagnostics, pharmaceuticals, and lab services at companies like Amersham and Nycomed.
The American Association for Cancer Research has appointed Mitchell Stoller to be executive director of the AACR Foundation for the Prevention and Cure of Cancer.
In the post, Stoller will head strategy and manage the development and expansion of fundraising and program activities. He has worked at several other large non-profit organizations, including the Nicholas Sparks Foundation, Safe Kids Worldwide, the Marrow Foundation, the Lance Armstrong Foundation, the Christopher Reeve Paralysis Foundation, and the Sudden Infant Death Syndrome Alliance.
Opko Health announced this week that it has appointed David Okrongly president of its diagnostics business unit.
Okrongly was previously chief operating officer of Exosome Diagnostics. Before that he was president and CEO of Quanterix as well as senior vice president of molecular diagnostics at Bayer Diagnostics.
Saladax Biomedical has hired John McAuliffe to be VP of companion diagnostics business development.
He formerly was director of business development at Athena Diagnostics, where he worked for 13 years in various roles and helped identify, evaluate, and launch more than 100 protein and molecular diagnostic assays.
Natural Molecular Testing said this week that it has named Keith Tyacke to be its chief financial officer. Tyacke recently was director of tax at Hauser Long and was a tax manager at the CPA firm Clothier and Head.
Pacific Biosciences has appointed John Milligan to its board of directors. Milligan is currently President and COO of Gilead Sciences. He has been at Gilead since 1990 and has served in a variety of roles, including research scientist and chief financial officer.
Cancer Genetics has appointed Keith Brownlie to serve on its board of directors and on the audit committee, bringing the total number of directors to eight.
Brownlie was an audit partner for a number of public companies in the life sciences, including Epicet and RXi Pharmaceuticals. He has been involved in more than 100 public and private financings and merger and acquisition deals, Cancer Genetics said.
Accelrys said this week that its stockholders have elected Heidi Melin to serve on its board of directors until 2016. Melin is the chief marketing officer of Plex Systems, and she formerly was senior VP and chief marketing officer at Eloqua. She also worked in marketing and management at Taleo, Polycom, Hyperion, and Peoplesoft.
She will serve on the Accelrys board's human resources committee and governance and nominating committee.
Trovagene's stockholders have approved all six of the nominees for its board of directors, all of whom are current directors, to serve until the 2014 annual stockholder meeting. These directors include Christopher McGuigan; Gary Jacob; Thomas Adams; John Brancaccio; Antonius Schuh; and Stanley Tennant.
Mimetas, a maker of organ-on-a-chip technologies, has named Herbert Heyneker to serve on its board of directors.
Heyneker was one of the first scientists at Genentech, and he later worked at Genencore as VP of R&D. He has held posts and served on the boards at other pharmaceutical firms as well.
The agricultural genomics firm Evogene has appointed Akiva Mozes and Ziv Kop to serve on its board of directors.
Mozes is chairman of Bazan Group's Oil Refinery, a member of the board of directors of Strauss Group, and he formerly was president and CEO of Israel Chemicals.
Kop is the founder and CEO of Go Capital, and he formerly was managing partner at Glenrock Israel and CEO of POC management consulting.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.